Only clinical trials help to reliably ascertain how to improve efficacy, while collecting data on the impact of adverse effects. Every well-conducted study, every participating site and patient contribute to an advanced care for tumor patients.
If you are interested in participating in a study, please don’t hesitate to contact us.
HR+/HER2-
Renal Cell Carcinoma
metastatic / locally advanced and inoperable
stage IV non-squamous NSCLC or extensive-stage SCLC
NSCLC, stage II - IV
HR-positive / HER2-negative, inoperable or metastatic
HER2/neu-negative, metastatic or locally advanced
NSCLC, metastatic / advanced and inoperable
advanced
HR pos / HER2 neg, metastasized / locally advanced & inoperable
advanced, metastatic
diffuse large B-cell lymphoma (DLBCL) untreated, CD20-positive
HR-positive / HER2-negative, with visceral metastases, postmenopausal
metastatic
metastatic / advanced and inoperable
metastatic, RAS wild-type